Articles

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia

Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel;
West Virginia University, Morgantown, WV, USA;
Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France;
Ospedale San Raffaele s.r.l., Milano, Italy;
Ospedale San Martino, Department of Haematology II, Genova, Italy;
Medical Park Hospitals, Stem Cell Transplant Unit, Antalya, Turkey;
Anadolu Medical Center Hospital, Bone Marrow Transplantation Department, Kocaeli, Turkey;
Tor Vergata University of Rome, Stem Cell Transplant Unit, Rome, Italy;
Klinikum Grosshadern, Med. Klinik III, Munich, Germany;
Ospedale San Gerardo, Clinica Ematologica dell`Universita Milano-Biocca, Monza, Italy;
Baskent University Hospital, Haematology Division, BMT Unit, Adana, Turkey;
First State Pavlov Medical University of St. Petersburg, Russia;
First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China;
Florence Nightingale Sisli Hospital, Hematopoietic SCT Unit, Istanbul, Turkey;
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia;
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland;
Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA;
Saint Antoine Hospital and Université Pierre et Marie Curie, Paris, France
Haematologica Early view Apr 30, 2020 https://doi.org/10.3324/haematol.2020.247296